Skip to content
Disclosery

BVF INC/IL

Follow

13F filer, CIK 1056807, San Francisco, CA

BVF INC/IL reported $2,799,144,005 across 44 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14. Its ten largest share positions make up 76.91% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000921895-25-002281

Period
2025-06-30
Reported value
$2.8B
Holdings
44
Top 10 weight
76.91%
New
3
Sold out
10

Part of the filer group BVF INC/IL

How groups are built

Stakes and trades reported after 2025-06-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • STOK STOKE THERAPEUTICS INC: 13G 3,608,968 shares, 5.6% of the class, 13G filed 2026-09-30, 0000921895-26-002685Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
PTGXadded+636,026$35.2M
IMCRnew+1,024,288$32.1M
CBIOnew+1,387,863$22.4M
KYMRadded+340,909$14.9M
RAPTnew+1,154,692$9.24M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LKFTexited-1,454,422-$36.5M
VERVE THERAPEUTICS INCexited-6,904,050-$31.6M
ITEOS THERAPEUTICS INCexited-3,075,000-$18.4M
RAPT THERAPEUTICS INCexited-9,237,556-$11.3M
XOMAreduced-392,723-$9.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0000921895-25-002281, largest first. % of portfolio is the value over $2,799,144,005, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 21,751,284 shares; 2024Q4: 19,751,284 shares; 2025Q1: 19,751,284 shares; 2025Q2: 19,751,284 shares 19,751,284$932M33.31%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,161,801 shares; 2024Q4: 5,161,801 shares; 2025Q1: 5,161,801 shares; 2025Q2: 5,502,710 shares 5,502,710$240M8.58%+340,909Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,478,612 shares; 2024Q4: 4,181,179 shares; 2025Q1: 4,982,384 shares; 2025Q2: 4,982,384 shares 4,982,384$183M6.55%0Timeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,850,167 shares; 2024Q4: 1,900,015 shares; 2025Q1: 2,575,015 shares; 2025Q2: 3,211,041 shares 3,211,041$177M6.34%+636,026Timeline
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,046,000 shares; 2024Q4: 1,388,064 shares; 2025Q1: 1,690,221 shares; 2025Q2: 1,690,221 shares 1,690,221$176M6.3%0Timeline
MIRMMIRUM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,075,907 shares; 2024Q4: 2,796,513 shares; 2025Q1: 2,796,513 shares; 2025Q2: 2,761,333 shares 2,761,333$141M5.02%-35,180Timeline
GHRSGH RESEARCH PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 10,400,158 shares; 2024Q4: 10,400,158 shares; 2025Q1: 8,827,712 shares; 2025Q2: 8,827,712 shares 8,827,712$108M3.84%0Timeline
IONSIONIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,451,879 shares; 2024Q4: not reported; 2025Q1: 1,913,385 shares; 2025Q2: 1,913,385 shares 1,913,385$75.6M2.7%0Timeline
XOMAXOMA ROYALTY CORPORATIONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,633,743 shares; 2024Q4: 3,633,743 shares; 2025Q1: 2,983,026 shares; 2025Q2: 2,590,303 shares 2,590,303$65.3M2.33%-392,723Timeline
ZYMEZYMEWORKS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,607,935 shares; 2024Q4: 4,308,935 shares; 2025Q1: 4,308,935 shares; 2025Q2: 4,308,935 shares 4,308,935$54.1M1.93%0Timeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,452,024 shares; 2025Q1: 4,396,124 shares; 2025Q2: 4,396,124 shares 4,396,124$46.5M1.66%0Timeline
CELCCELCUITY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,466,000 shares; 2024Q4: 3,466,000 shares; 2025Q1: 3,466,000 shares; 2025Q2: 3,466,000 shares 3,466,000$46.3M1.65%0Timeline
KURAKURA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,371,761 shares; 2024Q4: 2,567,469 shares; 2025Q1: 7,754,129 shares; 2025Q2: 7,754,129 shares 7,754,129$44.7M1.6%0Timeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,750,683 shares; 2024Q4: 5,750,683 shares; 2025Q1: 5,750,683 shares; 2025Q2: 5,750,683 shares 5,750,683$43.3M1.55%0Timeline
ACIUAC IMMUNE SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 19,522,436 shares; 2024Q4: 19,522,436 shares; 2025Q1: 19,822,436 shares; 2025Q2: 19,822,436 shares 19,822,436$40.2M1.44%0Timeline
CDTXCIDARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 703,065 shares; 2024Q4: 1,092,796 shares; 2025Q1: 924,642 shares; 2025Q2: 786,392 shares 786,392$38.3M1.37%-138,250Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,661,194 shares; 2024Q4: 3,944,194 shares; 2025Q1: 3,944,194 shares; 2025Q2: 3,944,194 shares 3,944,194$37.7M1.35%0Timeline
GPCRSTRUCTURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,238,986 shares; 2024Q4: 1,771,417 shares; 2025Q1: 1,771,417 shares; 2025Q2: 1,771,417 shares 1,771,417$36.7M1.31%0Timeline
IMCRIMMUNOCORE HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,024,288 shares 1,024,288$32.1M1.15%newTimeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,764,471 shares; 2025Q1: 5,660,132 shares; 2025Q2: 5,660,132 shares 5,660,132$25.5M0.91%0Timeline
FHTXFOGHORN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,302,000 shares; 2024Q4: 5,302,000 shares; 2025Q1: 5,302,000 shares; 2025Q2: 5,302,000 shares 5,302,000$24.9M0.89%02026-10-01, 13G/A: 8,507,000 shares, 14.3% of the class, 13G/A filed 2026-10-05 Timeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 9,135,893 shares; 2024Q4: 5,715,893 shares; 2025Q1: 5,295,893 shares; 2025Q2: 5,295,893 shares 5,295,893$22.6M0.81%0Timeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,387,863 shares 1,387,863$22.4M0.8%newTimeline
XNCRXENCOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 850,000 shares; 2024Q4: 2,288,760 shares; 2025Q1: 2,740,141 shares; 2025Q2: 2,740,141 shares 2,740,141$21.5M0.77%0Timeline
FDMT4D MOLECULAR THERAPEUTICS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 7,382,642 shares; 2024Q4: 2,670,642 shares; 2025Q1: 4,561,289 shares; 2025Q2: 4,629,289 shares 4,629,289$17.2M0.61%+68,000Timeline
ELDNELEDON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,293,282 shares; 2024Q4: 6,293,282 shares; 2025Q1: 6,293,282 shares; 2025Q2: 6,293,282 shares 6,293,282$17.1M0.61%0Timeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 7,000,000 shares; 2024Q4: 7,000,000 shares; 2025Q1: 7,000,000 shares; 2025Q2: 7,000,000 shares 7,000,000$16.8M0.6%0Timeline
PVLAPALVELLA THERAPEUTICS INC NEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 696,555 shares; 2025Q1: 696,555 shares; 2025Q2: 696,555 shares 696,555$15.7M0.56%0Timeline
ESSA PHARMA INCESSA PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,748,629 shares; 2024Q4: 8,748,629 shares; 2025Q1: 8,748,629 shares; 2025Q2: 8,748,629 shares 8,748,629$14.9M0.53%0
REPARE THERAPEUTICS INCREPARE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 10,333,600 shares; 2024Q4: 10,333,600 shares; 2025Q1: 10,333,600 shares; 2025Q2: 10,333,600 shares 10,333,600$14.4M0.51%0
VSTMVERASTEM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,685,219 shares; 2024Q4: 2,100,468 shares; 2025Q1: 2,100,468 shares; 2025Q2: 3,404,425 shares 3,404,425$14.1M0.5%+1,303,957Timeline
RAPTRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,154,692 shares 1,154,692$9.24M0.33%newTimeline
FBRXFORTE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 119,282 shares; 2024Q4: 594,282 shares; 2025Q1: 594,282 shares; 2025Q2: 588,344 shares 588,344$7.61M0.27%-5,938Timeline
TCRXTSCAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,989,474 shares; 2024Q4: 2,989,474 shares; 2025Q1: 4,889,474 shares; 2025Q2: 5,226,074 shares 5,226,074$7.58M0.27%+336,600Timeline
IKENA ONCOLOGY INCIKENA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,769,164 shares; 2024Q4: 4,006,564 shares; 2025Q1: 4,006,564 shares; 2025Q2: 4,006,564 shares 4,006,564$5.37M0.19%0
IMUXIMMUNIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,902,972 shares; 2024Q4: 8,902,972 shares; 2025Q1: 8,902,972 shares; 2025Q2: 7,652,972 shares 7,652,972$5.34M0.19%-1,250,000Timeline
MOLNMOLECULAR PARTNERS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 443,221 shares; 2024Q4: 1,353,968 shares; 2025Q1: 1,353,968 shares; 2025Q2: 1,353,968 shares 1,353,968$5.19M0.19%0Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 967,000 shares; 2024Q4: 1,036,679 shares; 2025Q1: 1,036,679 shares; 2025Q2: 1,028,049 shares 1,028,049$5.13M0.18%-8,630Timeline
IVAINVENTIVA SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 686,040 shares; 2024Q4: 686,040 shares; 2025Q1: 686,040 shares; 2025Q2: 686,040 shares 686,040$2.14M0.08%0Timeline
TENXTENAX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 339,549 shares; 2024Q4: 339,549 shares; 2025Q1: 339,549 shares; 2025Q2: 339,549 shares 339,549$1.98M0.07%0Timeline
SABSSAB BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 917,826 shares; 2024Q4: 917,826 shares; 2025Q1: 917,826 shares; 2025Q2: 917,826 shares 917,826$1.61M0.06%0Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,853,818 shares; 2024Q4: 3,853,818 shares; 2025Q1: 3,853,818 shares; 2025Q2: 3,853,818 shares 3,853,818$1.27M0.05%0Timeline
ENGNWENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 945,402 shares; 2024Q4: 945,402 shares; 2025Q1: 945,402 shares; 2025Q2: 945,402 shares 945,402$586K0.02%0Timeline
NLS PHARMACEUTICS LTDNLS PHARMACEUTICS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 143,676 shares; 2024Q4: 143,676 shares; 2025Q1: 143,676 shares; 2025Q2: 143,676 shares 143,676$417K0.01%0

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
LKFTLAKEFRONT BIOTHERAPEUTICS NV1,454,422$36.5Mshares
VERVE THERAPEUTICS INCVERVE THERAPEUTICS INC6,904,050$31.6Mshares
ITEOS THERAPEUTICS INCITEOS THERAPEUTICS INC3,075,000$18.4Mshares
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC9,237,556$11.3Mshares
THRDTHIRD HARMONIC BIO INC2,372,933$8.23Mshares
VIGIL NEUROSCIENCE INCVIGIL NEUROSCIENCE INC4,013,633$7.14Mshares
ALLAKOS INCALLAKOS INC16,552,417$3.77Mshares
CTMXCYTOMX THERAPEUTICS INC.5,228,461$3.32Mshares
GLYCOMIMETICS INCGLYCOMIMETICS INC9,544,262$2Mshares
NAMSNEWAMSTERDAM PHARMA COMPANY59,065$1.21Mshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000921895-25-002281 base2025-08-14acceptance time not in the bulk data set